BioSpace News Archive

Job Trends

Sonoma, Thermo Fisher Bring Jobs to Seattle, WA & Plainville, MA - Updated

Sonoma Bio announced its plans to erect an 83,000-square-foot operations facility in Seattle, while Thermo Fisher opened a new viral vector manufacturing plant in Massachusetts.

August 24, 2022
·
3 min read
·
Tristan Manalac
Scientists Behind COVID-19 RECOVERY Trial Turn Attention to Monkeypox

The Oxford University team behind the global COVID-19 RECOVERY study is now focusing its attention on developing a new monkeypox treatment.

August 24, 2022
·
2 min read
·
Vanessa Doctor, RN
Business

Money on the Move: AdvanCell, eTheRNA, Bluejay and More

Money is now flowing into promising platforms for prostate cancer from AdvanCell, mRNA therapeutics from eTheRNA, hepatitis from Bluejay and more.

August 24, 2022
·
5 min read
·
Tristan Manalac
Global Roundup: Sputnik V Adapted, AB Science Submits ALS Drug in EU and More

Russian researchers announced a new Sputnik V vaccine against the Delta and Omicron variants of COVID-19, AB Science files for conditional marketing approval of its ALS drug in the EU and much more.

August 24, 2022
·
4 min read
·
Alex Keown
Business

Aeglea CEO Steps Down as Restructure Claims 25% of Workforce

Anthony Quinn has stepped down from his role as chief executive officer and transitioned to an advisory role. Jim Kastenmayer, general counsel, will assume the post on an interim basis.

August 24, 2022
·
2 min read
·
Alex Keown
Drug Development

Novartis’ Plan to Repurpose SMA Drug for Huntington’s Runs into Side Effects

Novartis announced Wednesday it is temporarily halting dosing in its ongoing Phase IIb VIBRANT-HD trial of branaplam in Huntington’s disease.

August 24, 2022
·
2 min read
·
Mark Terry
Aktis Banks Another $84M to Bring Radiopharmaceuticals to the Masses

Aktis Oncology announced it has completed an $84 million financing round to bring its class of targeted radiopharmaceuticals to a large patient pool with a broad range of tumor types.

August 24, 2022
·
2 min read
·
Rosemary Scott
Business

3T Biosciences Launches $40M at Solid Tumors with TCR Tech

Bay Area-based 3T Biosciences launched Thursday with a technology platform its leadership team believes can change the future of treatment for solid tumors and immune-mediated diseases.

August 24, 2022
·
4 min read
·
Alex Keown
Business

77 Jobs on the Chopping Block as Atara Pivots Pipeline Strategy

Layoffs at Atara have begun weeks after the Bay Area company announced plans to terminate 20% of its staff under a new corporate strategy focused on the innovation within the company’s pipeline.

August 24, 2022
·
3 min read
·
Alex Keown
Drug Development

AstraZeneca Reportedly Seeking Bolt-On Opportunities, could Abandon Vaccines

In an interview with Reuters, AstraZeneca CEO Pascal Soriot said Tuesday that he isn’t sure if the company will continue developing vaccines. He also hinted at potential M&A action.

August 24, 2022
·
3 min read
·
Mark Terry